학술논문
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Document Type
Article
Author
Kristeleit, Rebecca ; Lisyanskaya, Alla; Fedenko, Alexander; Dvorkin, Mikhail; de Melo, Andreia Cristina; Shparyk, Yaroslav; Rakhmatullina, Irina; Bondarenko, Igor; Colombo, Nicoletta; Svintsitskiy, Valentyn; Biela, Luciano; Nechaeva, Marina; Lorusso, Domenica; Scambia, Giovanni; Cibula, David; Póka, Róbert; Oaknin, Ana; Safra, Tamar; Mackowiak-Matejczyk, Beata; Ma, Ling; Thomas, Daleen; Lin, Kevin K; McLachlan, Karen; Goble, Sandra; Oza, Amit M
Source
In The Lancet Oncology April 2022 23(4):465-478
Subject
Language
ISSN
1470-2045